Argen-X
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgarti… Read more
Argen-X (1AE) - Total Liabilities
Latest total liabilities as of June 2025: €1.08 Billion EUR
Based on the latest financial reports, Argen-X (1AE) has total liabilities worth €1.08 Billion EUR as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Argen-X - Total Liabilities Trend (2016–2024)
This chart illustrates how Argen-X's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Argen-X Competitors by Total Liabilities
The table below lists competitors of Argen-X ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Essilor International SA
PINK:ESLOY
|
USA | $23.52 Billion |
|
Muench. Rueckvers. VNA O.N.
LSE:0KFE
|
UK | €246.71 Billion |
|
UH3
F:UH3
|
Germany | €11.64 Billion |
|
Garmin Ltd
NYSE:GRMN
|
USA | $2.02 Billion |
|
Westinghouse Air Brake Technologies Corp
NYSE:WAB
|
USA | $10.43 Billion |
|
Crown Castle International Corp.
LSE:0I4W
|
UK | $33.15 Billion |
|
MSCI Inc
NYSE:MSCI
|
USA | $8.36 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down Argen-X's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.60 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Argen-X's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Argen-X (2016–2024)
The table below shows the annual total liabilities of Argen-X from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €704.24 Million | +58.27% |
| 2023-12-31 | €444.95 Million | +38.80% |
| 2022-12-31 | €320.56 Million | +1.43% |
| 2021-12-31 | €316.05 Million | -35.93% |
| 2020-12-31 | €493.32 Million | +28.94% |
| 2019-12-31 | €382.59 Million | +854.98% |
| 2018-12-31 | €40.06 Million | +54.22% |
| 2017-12-31 | €25.98 Million | -38.73% |
| 2016-12-31 | €42.40 Million | -- |